Sandu Pharmaceuticals

Sandu Pharmaceuticals PEG

The PEG Ratio (Price/Earnings-to-Growth) of Sandu Pharmaceuticals (524703.BO) as of Oct 31, 2026 is 3.55. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 4.04 — a change of -12.30% (lower).

PEG

3.55

YoY

-12.30%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Sandu Pharmaceuticals is 2026 3.55 . PEG Ratio (Price/Earnings-to-Growth) of Sandu Pharmaceuticals was 2025 4.04 . It decreases by -12.30% lower compared to the previous year.

The Sandu Pharmaceuticals PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2019
9.36 INR
Jan 1, 2020
8.70 INR
Jan 1, 2021
5.73 INR
Jan 1, 2022
3.94 INR
Jan 1, 2023
4.12 INR
Jan 1, 2024
4.29 INR
Jan 1, 2025
4.04 INR
Jan 1, 2026
3.55 INR
The Sandu Pharmaceuticals PEG history
YEARPEGYoY
3.55-12.30%
4.04-5.67%
4.29+4.07%
4.12+4.54%
3.94-31.27%
5.73-34.07%
8.70-7.11%
9.36-16.08%
11.16-24.53%
14.78+26.93%
11.65-23.10%
15.14+19.95%
12.63—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sandu Pharmaceuticals Stock analysis

What does Sandu Pharmaceuticals do? Sandu Pharmaceuticals Ltd is a Mumbai-based company operating in the Consumer Staples sector, specifically within the consumer products industry. Listed on September 26, 1994, the firm manufactures and markets Ayurvedic medicines. Its product portfolio spans digestive health, immunity, muscle and bone health, respiratory health, and general wellness. Specific offerings address conditions such as constipation, hyperacidity, asthma, and colds, while also covering female, male, and mother-and-child wellness. The company utilizes in-house know-how from Sandu Brothers Private Limited for production and distributes its goods, including immunity kits and power herbs, through e-commerce marketplaces. Sandu Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sandu Pharmaceuticals stock

PEG Ratio (Price/Earnings-to-Growth) of Sandu Pharmaceuticals is 3.55 in 2026.

PEG Ratio (Price/Earnings-to-Growth) of Sandu Pharmaceuticals changed from 4.04 to 3.55, representing a -12.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Sandu Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Sandu Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Sandu Pharmaceuticals

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Sandu Pharmaceuticals